Targeting bacterial proteins to treat inflammatory bowel diseases
Official title: Targeting bacterial proteases involved in PAR signaling to treat inflammatory bowel diseases
Funded at Stanford University · NIH-10911223 · Data updated 2026-11-12
This study is looking at how certain bacteria in the gut might affect inflammation and the protective barrier in people with inflammatory bowel diseases like Crohn's and ulcerative colitis, with the hope of finding new ways to help ease their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 21, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $438,309 |
| NIH project number | 5R01DK130293-04 |
| Project ID | NIH-10911223 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Crohn's disease or ulcerative colitis who are experiencing severe symptoms.
✕Less likely to help
Patients with IBD who are in remission or those with other gastrointestinal disorders unrelated to protease activity may not benefit from this research.
What this research studies
This research investigates the role of bacterial proteases in the signaling pathways that contribute to inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis. By understanding how these proteases affect the gut's barrier function and inflammation, the research aims to identify new therapeutic targets. Patients with IBD often experience debilitating symptoms, and this study seeks to explore innovative treatments that could alleviate these issues. The approach involves analyzing the interactions between bacterial proteins and the body's signaling mechanisms to develop potential new therapies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the symptoms and improve the quality of life for patients with inflammatory bowel diseases.
How similar studies have gone: Previous research has shown promise in targeting protease signaling pathways for treating gastrointestinal diseases, indicating that this approach could be effective.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Bogyo, Matthew — Stanford University
- Study coordinator: Bogyo, Matthew
Related research
Other NIH-funded projects on the same topics.
-
Comparative care for IBD in Hispanic patients
A Mayo Clinic Arizona team will study how Crohn’s disease and ulcerative colitis progress and respond to treatments in Hispanic patients using real-world data.
-
Understanding why some people with inflammatory bowel disease fail therapy
A physician-scientist at UNC is pursuing why inflammatory bowel disease treatment stops working so therapies can be kept effective longer.
-
Celiac and IBD: unlocking how genes influence disease with DNA methylation
A research project aims to use genetic and epigenetic clues to better understand why celiac disease and inflammatory bowel disease affect people differently and how they respond to treatment.
-
How genes and DNA changes influence celiac disease and inflammatory bowel disease
This project looks for DNA changes that alter gene activity to help predict risk, severity, and treatment response for people with celiac disease and inflammatory bowel disease.
-
Understanding what triggers inflammation in inflammatory bowel diseases
This study is looking at what causes inflammation in people with Crohn's disease and ulcerative colitis who are feeling really well, to help find ways to keep them healthy and prevent flare-ups in the future.
-
Finding ways to block bacterial enzymes that worsen inflammatory bowel diseases
This project looks for new ways to treat inflammatory bowel diseases like Crohn's and ulcerative colitis by targeting specific enzymes made by gut bacteria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.